{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:15:59Z","timestamp":1787166959433,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","nmd-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.nmd.2024.05.008","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T12:55:43Z","timestamp":1715950543000},"page":"7-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Further expanding the phenotype of anti-Ku antibody associated disease in children and adolescents"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1065-2363","authenticated-orcid":false,"given":"Ezgi Deniz","family":"Batu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seher","family":"\u015eener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6knur","family":"Halilo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beril","family":"Talim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bur\u00e7in","family":"\u015eener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00dcmit Murat","family":"\u015eahiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelda","family":"Bilginer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diclehan","family":"Orhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00dcst\u00fcn","family":"Ayd\u0131ng\u00f6z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seza","family":"\u00d6zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2024.05.008_bib0001","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.2169\/internalmedicine.41.1096","article-title":"Clinical significance of anti-Ku autoantibodies\u2013a serologic marker of overlap syndrome?","volume":"41","author":"Mimori","year":"2002","journal-title":"Intern Med"},{"key":"10.1016\/j.nmd.2024.05.008_bib0002","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1172\/JCI110295","article-title":"Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap","volume":"68","author":"Mimori","year":"1981","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2024.05.008_bib0003","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2018-214439","article-title":"Anti-Ku syndrome with elevated CK and anti-Ku syndrome with anti-dsDNA are two distinct entities with different outcomes","volume":"78","author":"Spielmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2024.05.008_bib0004","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1093\/rheumatology\/kead049","article-title":"Anti-Ku antibody syndrome: is it a distinct clinical entity? A cross-sectional study of 75 patients","volume":"62","author":"Sousa","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2024.05.008_bib0005","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.semarthrit.2021.04.012","article-title":"The phenotype of myositis patients with anti-Ku autoantibodies","volume":"51","author":"Casal-Dominguez","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.nmd.2024.05.008_bib0006","doi-asserted-by":"crossref","first-page":"e4713","DOI":"10.1097\/MD.0000000000004713","article-title":"Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations","volume":"95","author":"Hoa","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nmd.2024.05.008_bib0007","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1007\/s10067-023-06687-5","article-title":"Anti-Ku antibody-positive systemic sclerosis and idiopathic inflammatory myopathies overlap syndrome in children: a report of two cases and a review of the literature","volume":"42","author":"Kanda","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nmd.2024.05.008_bib0008","unstructured":"International Consensus on Antinuclear Antibody (ANA) Patterns (ICAP), https:\/\/anapatterns.org\/, 2023 [accessed on 19 January 2023]."},{"key":"10.1016\/j.nmd.2024.05.008_bib0009","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.semarthrit.2020.10.007","article-title":"Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis","volume":"51","author":"Sag","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.nmd.2024.05.008_bib0010","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/pde.14243","article-title":"Anti-Ku antibody-positive systemic sclerosis-polymyositis overlap syndrome in an adolescent","volume":"37","author":"Loo","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.nmd.2024.05.008_bib0011","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/ced.14937","article-title":"Anti-Ku-positive juvenile dermatomyositis","volume":"47","author":"Cotter","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.nmd.2024.05.008_bib0012","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/art.1780360318","article-title":"Localized scleroderma progressing to systemic disease. Case report and review of the literature","volume":"36","author":"Birdi","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2024.05.008_bib0013","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1525-1470.2000.017005381.x","article-title":"A juvenile case of overlap syndrome of systemic lupus erythematosus and polymyositis, later accompanied by systemic sclerosis with the development of anti-Scl 70 and anti-Ku antibodies","volume":"17","author":"Nitta","year":"2000","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.nmd.2024.05.008_bib0014","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1111\/pde.12644","article-title":"Childhood-onset anti-ku antibody-positive generalized morphea with polymyositis: a japanese case study","volume":"32","author":"Kishi","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.nmd.2024.05.008_bib0015","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209268","article-title":"Pathologic Features of Anti-Ku Myositis","volume":"102","author":"Oyama","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2024.05.008_bib0016","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/mrcr\/rxab024","article-title":"Anti-Ku antibody-positive myositis presenting as a wide range of axial myopathies and myocarditis: a case report and review of the literature","volume":"6","author":"Kono","year":"2022","journal-title":"Mod Rheumatol Case Rep"},{"key":"10.1016\/j.nmd.2024.05.008_bib0017","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jneuroim.2014.07.006","article-title":"Clinical and histological findings associated with autoantibodies detected by RNA immunoprecipitation in inflammatory myopathies","volume":"274","author":"Suzuki","year":"2014","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.nmd.2024.05.008_bib0018","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/MD.0b013e31824d9cec","article-title":"Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease","volume":"91","author":"Rigolet","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nmd.2024.05.008_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102851","article-title":"Histopathological features of systemic sclerosis-associated myopathy: a scoping review","volume":"20","author":"Lefebvre","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nmd.2024.05.008_bib0020","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/jdv.12840","article-title":"Hutchinson-Gilford progeria syndrome with scleroderma-like skin changes due to a homozygous missense LMNA mutation","volume":"30","author":"Zhang","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.nmd.2024.05.008_bib0021","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/ajmg.a.33018","article-title":"Progeroid syndrome with scleroderma-like skin changes associated with homozygous R435C LMNA mutation","volume":"149A","author":"Madej-Pilarczyk","year":"2009","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.nmd.2024.05.008_bib0022","first-page":"303","article-title":"Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options","volume":"35","author":"Fredi","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nmd.2024.05.008_bib0023","first-page":"1393","article-title":"Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients","volume":"29","author":"Franceschini","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2024.05.008_bib0024","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","article-title":"Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset","volume":"53","author":"Tansley","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2024.05.008_bib0025","article-title":"Is Anti-NXP2 Autoantibody a Risk Factor for Calcinosis and Poor Outcome in Juvenile Dermatomyositis Patients?","volume":"9","author":"Toplak","year":"2021","journal-title":"Case Series. Front Pediatr"},{"key":"10.1016\/j.nmd.2024.05.008_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152133","article-title":"Early-onset juvenile dermatomyositis: a tertiary referral center experience and review of the literature","volume":"58","author":"Sener","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.nmd.2024.05.008_bib0027","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1136\/annrheumdis-2019-216595","article-title":"Response to: 'Anti-Ku antibodies: important points to consider' by Mahler et al","volume":"80","author":"Ogawa-Momohara","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896624001056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896624001056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T20:32:47Z","timestamp":1716841967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896624001056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":27,"alternative-id":["S0960896624001056"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2024.05.008","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Further expanding the phenotype of anti-Ku antibody associated disease in children and adolescents","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2024.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}